Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > REGULATORY
REGULATORY
- MHLW Orders Revision of Package Inserts for Acetaminophen
October 24, 2014
- Trade Groups Seek Insurance Coverage for Conditionally Approved Regenerative Medicine Products
October 24, 2014
- Chuikyo OKs New Review Organs for Regenerative Medicines and Medical Devices under Senshin-Iryo System
October 24, 2014
- Chuikyo Begins Discussions on Patient-Initiated Mixed-Care System
October 24, 2014
- Online Document Filings for Healthcare Product Import/Export Possible from November
October 23, 2014
- Shiozaki Sounds Positive about Fact-Finding Study for Yearly NHI Price Cuts
October 23, 2014
- NIBIO, PMDA Join Hands in Advisory Services to Bring Academic Seeds to Market
October 22, 2014
- Editor’s Pick: Five Healthcare News Headlines for October 6 - October 17
October 21, 2014
- Takeda Takes Over Development of Glatiramer Acetate from Teva: Official
October 21, 2014
- Health Ministry Eyes Future Genomic Data Registration at National Medical Centers
October 21, 2014
- Applications Based on the Revised PAL to Be Accepted from Nov. 25
October 17, 2014
- MHLW to Report Lantus Biosimilars to PAFSC First Committee on Oct. 29
October 17, 2014
- NIBIO to Begin Drug Seed Optimization Project from FY2015
October 16, 2014
- PAFSC Second Committee to Discuss Janssen’s Combination Tablet for HIV Infection on Oct. 27
October 16, 2014
- 4 Die after Taking SGLT-2 Inhibitors, Causality under Scrutiny
October 15, 2014
- Japan Faces Rocky Road to Ratify Nagoya Protocol on Biodiversity
October 15, 2014
- MHLW Panel OKs Tweaked Requirements for New Development Request Scheme
October 15, 2014
- Council OKs Public-Knowledge Based Application for Solu-Cortef as a Treatment for Bronchial Asthma
October 15, 2014
- Govt Panel Says New Mixed-Care Scheme Is “Patient-Initiated” but Current System Isn’t
October 14, 2014
- National Healthcare Expenditure Hits Record 39 Trillion Yen in FY2012
October 14, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…